Bayer's Balancing Act: A $5bn Bond Coup and a Debt Target That Just Got Bolder

Bayer's $5B bond sale and strong Q2 results signal a turning point, with debt target cut and Apollo investment boosting confidence.

The market's verdict on Bayer is becoming easier to read by the week. Fresh off a second-quarter earnings beat that sent analysts scrambling to lift their price targets, the Leverkusen-based conglomerate has now added a $5bn US dollar bond sale to its list of accomplishments — a five-tranche deal spanning maturities from five to 30 years that drew multiple times oversubscription. For a company that has spent the better part of two years wrestling with litigation overhang and a heavy debt load, the warm reception from institutional investors signals something close to a turning point.

The bond placement, completed in July, arrived just days after Bayer reported quarterly numbers that comfortably cleared consensus. Revenue for the second quarter of 2026 rose 1.2 percent to EUR 10.87bn, while adjusted EBITDA climbed 1.9 percent to EUR 2.14bn — comfortably ahead of the EUR 1.94bn analysts had penciled in. The adjusted earnings per share figure proved even more striking, landing at EUR 0.95, a full 26.5 percent above the average analyst estimate.

Crop Science carries the quarter, Pharma weighs

The engine behind the beat was once again Crop Science, where operating profit surged 30.2 percent to EUR 902m. Higher glyphosate prices and the US Environmental Protection Agency's re-approval of dicamba herbicides gave the agricultural division meaningful tailwinds. The pharma arm, by contrast, moved against the grain: operating profit slipped 3.6 percent as Bayer stepped up marketing spending on Nubeqa and Kerendia, investments aimed at winning market share but currently pressuring margins.

The agribusiness is also being reshaped from within. In early July, Bayer carved its US glyphosate operations into a standalone subsidiary called Ruveon, headquartered in St. Louis. The new entity is designed to respond more nimbly to pricing pressure and generic competition as part of a multi-year restructuring programme. Notably, Ruveon recently withdrew its anti-dumping petitions against Chinese glyphosate imports, bowing to pressure from US farming groups concerned about rising herbicide costs for growers.

Debt reduction accelerates — with caveats

Perhaps the most consequential development came on the balance-sheet front. Bayer has lowered its year-end 2026 net financial debt target from EUR 32–33bn to EUR 29–30bn, a revision made possible by a EUR 3bn investment from Apollo Global Management into the company's LARC business. Bayer retains majority ownership and operational control, with the transaction expected to close in the third quarter of 2026.

The improved outlook comes with important qualifications. Bayer confirmed that legal payments of around EUR 4.3bn will still be incurred in 2026, and free cash flow is expected to remain negative. Net financial debt stood at EUR 33.647bn as of June 30 — up 3.5 percent quarter-on-quarter, though only 1.1 percent higher year-on-year. Free cash flow in the second quarter was minus EUR 371m, weighed down in part by higher glyphosate-related litigation payments.

Analysts split on how much upside remains

The combination of a strong quarter and accelerated deleveraging triggered a wave of price-target upgrades. Goldman Sachs lifted its target from EUR 62.50 to EUR 63.50, maintaining a "Buy" rating. Analyst James Quigley pointed to the solid financial performance, the resilient pharma business and clearer glyphosate risk as key drivers, while flagging potential upside from a narrowing of the conglomerate discount should a breakup materialise. UBS's Matthew Weston was more aggressive, raising his target from EUR 52 to EUR 62 with a "Buy" recommendation, noting that core operating results came in roughly 10 percent above consensus. The DZ Bank also moved, increasing its fair value from EUR 54 to EUR 60 with a "Buy" stance, citing operational progress, debt reduction and easing US legal risks.

Not everyone is chasing the rally, however. JPMorgan reaffirmed its "Overweight" rating in early August but left its price target unchanged at EUR 50 — close to where the shares currently trade. Analyst Richard Vosser acknowledged the strong results and confirmed full-year guidance, but his steady target suggests the recent share-price advance has already priced in much of the good news.

The legal calendar keeps sliding

The one cloud that refuses to fully lift is Roundup. The multibillion-dollar class-action settlement, valued at up to $7.25bn, remains pending final court approval. A hearing originally scheduled for August 19 has been pushed back to September 14 or later to allow more time to process opt-out requests. A final decision is still expected within 2026.

Bayer did receive significant legal relief in June when the US Supreme Court ruled 7-2 in the company's favour in the Durnell case, finding that federal law preempts state-level claims over missing cancer warnings. The decision strips the legal foundation from thousands of pending lawsuits. Bayer had argued that the EPA does not classify glyphosate as carcinogenic, making such warning labels impermissible in the first place — a position the court's ruling now supports.

The shares closed Friday at EUR 49.90, up 5.23 percent over the week, with the stock trading roughly 8 percent below its 52-week high of EUR 53.86 set in early July. The November third-quarter report will be the next major test of whether the positive momentum in Crop Science and the balance-sheet story can be sustained — and whether the bond market's vote of confidence translates into lasting equity-market conviction.